Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| MAZE | Maze Therapeutics | $31.73 | -$17.27 | -35.24% | 8.2M | $2.4B | $6.71$53.65 |
| AVXL | Anavex Life Sciences | $2.74 | -$1.46 | -34.73% | 385.6K | $388M | $2.62$13.99 |
| FCUV | Focus Universal | $3.38 | -$1.20 | -26.20% | 123.4K | $4.5M | $2.74$61.40 |
| PTLE | Ptl | $5.55 | -$1.61 | -22.49% | 193.7K | $45M | $4.00$156.00 |
| DPRO | Draganfly | $4.94 | -$1.39 | -21.96% | 195.6K | $147M | $1.63$14.40 |
| VELO | Velo3D | $10.63 | -$2.89 | -21.38% | 6.6M | $333M | $1.43$23.84 |
| RKLZ | Tidal Trust II - Defiance Daily Target 2x Short Rklb ETF | $20.88 | -$5.45 | -20.70% | 3.7M | - | $18.08$204.07 |
| NOMA | Nomadar | $3.44 | -$0.81 | -19.13% | 33.2K | $64M | $2.00$57.70 |
| FGL | Founder Group | $3.63 | -$0.80 | -18.06% | 554.3K | $75M | $3.10$154.00 |
| ABTS | Abits Group | $2.20 | -$0.48 | -17.91% | 14.4K | $6.4M | $1.35$10.86 |
| CNTX | Context Therapeutics | $2.65 | -$0.53 | -16.67% | 63K | $292M | $0.49$3.62 |
| ARTL | Artelo Biosciences | $4.85 | -$0.94 | -16.23% | 3.3M | $4.1M | $3.15$85.80 |
| SMCZ | Tidal Trust II - Defiance Daily Target 2x Short Smci ETF | $42.98 | -$8.23 | -16.07% | 878K | - | $19.85$225.57 |
| ADMA | Adma Biologics | $9.61 | -$1.73 | -15.22% | 1.2M | $2.7B | $8.62$25.67 |
| NPT | Texxon | $6.31 | -$1.09 | -14.73% | 115.6K | $164M | $3.14$22.38 |
| SKYQ | Sky Quarry | $2.20 | -$0.37 | -14.40% | 147.4K | $9.6M | $1.66$15.52 |
| YDDL | One And One Green Technologies. | $10.30 | -$1.70 | -14.17% | 314.5K | $648M | $3.61$12.01 |
| HSPT | Horizon Space Acquisition II Corp. | $7.19 | -$0.71 | -8.99% | 360 | $72M | $7.00$14.31 |
Related Articles
Featured Article
Wall Street Thinks This Small-Cap Stock Can Quadruple in Value
David Jagielski, CPA|Mar 15, 2023
The company generates no revenue, but it may be worth taking a chance on as it possesses lots of upside.
Is Anavex Life Sciences Stock a Buy Now?
David Jagielski, CPA|Feb 23, 2023
A short squeeze could be a possibility if the company can prove that bearish investors are wrong about its business.
This Short-Squeeze Candidate Could Actually Pan Out in the Long Run
George Budwell, PhD|Feb 9, 2023
Short-sellers have piled into this clinical-stage biopharma stock.
Why Has Cathie Wood Bought This Stock for Seven Days in a Row?
Rick Munarriz|Feb 8, 2023
The iconic growth stock investor keeps adding to an obscure 3D stock. She might be onto something.
Stocking Stuffers: 2 Stocks Trading Under $2
Rick Munarriz|Dec 27, 2022
Stocks with really low prices are risky, but it doesn't mean they can't move higher if they clear their hurdles.
Anavex Life Sciences Stock Could 5x Before 2025 -- Here's Why
Alex Carchidi|Dec 17, 2022
The biotech will first need to assuage the concerns of experts by elaborating on its latest clinical trial data.
Is Anavex Life Sciences a Buy?
Alex Carchidi|Dec 13, 2022
It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's.
Is Anavex Life Sciences a Smart Stock to Buy Now?
Cory Renauer|Dec 3, 2022
The company's Alzheimer's disease drug just succeeded in a clinical trial. Or did it?
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Rick Munarriz|Nov 17, 2022
The growth-focused money manager is making moves.
3D Printing Is About to Explode; Here's 1 Way to Profit From It
Taylor Carmichael|Sep 27, 2022
After many years of disappointment, the promise of 3D printing is about to be fulfilled -- and Velo3D could be the top dog and first mover.
